Pirlindole mesylate

Pricing Availability Delivery Time Qty
Cat.No. 0724 - Pirlindole mesylate | C15H18N2.CH3SO3H | CAS No. 207572-66-5
Description: MAO-A inhibitor
Chemical Name: 2,3,3a,4,5,6-Hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole mesylate
Datasheet
Citations
Literature

Biological Activity

A highly selective reversible inhibitor of monoamine oxidase type A.

Technical Data

M. Wt 322.42
Formula C15H18N2.CH3SO3H
Storage Store at RT
CAS Number 207572-66-5
PubChem ID 2829432
InChI Key PVUYTBQAVAYLDE-UHFFFAOYSA-N
Smiles CS(O)(=O)=O.CC1=CC=C2N3CCNC4CCCC(C2=C1)=C34

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 16.12 50mM with gentle warming

Preparing Stock Solutions

The following data is based on the product molecular weight 322.42. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.1 mL 15.51 mL 31.02 mL
5 mM 0.62 mL 3.1 mL 6.2 mL
10 mM 0.31 mL 1.55 mL 3.1 mL
50 mM 0.06 mL 0.31 mL 0.62 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis is currently unavailable
on-line. Please contact Customer Service.
Safety Datasheet

References

References are publications that support the products' biological activity.

Mashkovsky and Andreeva (1981) Pharmacological properties of 2,3,3α,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride (pirlindole), a new antidepressant. Arzneim.-Forsch.Drug Res. 31 75 PMID: 7194096

Medvedev et al (1992) Efficacy of pirlindole, a highly selective reversible inhibitor of monoamine oxidase type A in the prevention of experimentally induced epiletic seizures. Drug Investigation. 4 501 PMID:


If you know of a relevant reference for Pirlindole mesylate, please let us know.

View Related Products by Product Action

View all Monoamine Oxidase Inhibitors

Keywords: MAO-A inhibitors inhibits MAO Monoamine Oxygenases Oxidases Monoamine Oxidase

Citations for Pirlindole mesylate

Citations are publications that use Tocris products.

Currently there are no citations for Pirlindole mesylate. Do you know of a great paper that uses Pirlindole mesylate from Tocris? If so please let us know.

Commented out for usability testing

Reviews

TODO: Add Reviews

Literature in this Area

Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Addiction

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Pathways for Pirlindole mesylate

Protocols

TODO: Add Protocols